Our Philadelphia Januvia drug injury lawyers are evaluating cases from people who have suffered personal injuries, including pancreatic cancer, after using the type-2 diabetes drug Januvia. Merck & Co., the manufacturer of Januvia, may be liable for dangerous Januvia complications and side effects, including:
- hemorrhagic and necrotizing pancreatitis
- pancreatic duct metaplasia
- pancreatic cancer
- thyroid cancer
- renal (kidney) failure
- lactic acidosis
- severe joint pain
- wrongful death
Januvia and Pancreatic Cancer
Incretin hormones stimulate the pancreas’s release of insulin to lower blood sugar, a function that is often compromised in type-2 diabetics. Januvia is a dipeptidyl peptidase-4 (DPP-4) inhibitor incretin therapy drug that increases the level of natural incretin hormones in a type-2 diabetic’s bloodstream. While Januvia helps to reduce high blood sugar following a meal, it may also increase a patient’s risk of pancreatic cancer. Other incretin therapy drugs and incretin mimetics include:
- Onglyza (see Philadelphia Onglyza Drug Injury Lawyers)
- Janumet (see Philadelphia Janumet Drug Injury Lawyers)
- Victoza (see Philadelphia Victoza Drug Injury Lawyers)
- Byetta (see Philadelphia Byetta Drug Injury Lawyers)
- Bydureon (see Philadelphia Bydureon Drug Injury Lawyers)
- Janumet XR
Januvia FDA Warnings and Studies
Study results reported in a July 2011 issue of Gastroenterology revealed a six-fold increase in risk of pancreatitis and an increased risk of pancreatic cancer with incretin therapy. Drugs included in the study were dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagonlike peptide 1 (GLP-1) receptor agonists.
On March 14, 2013, the U.S. Food and Drug Administration (FDA) released a drug safety communication reporting the possibility of an increased risk of pancreatitis and pancreatic duct metaplasia in users of Januvia and similar drugs.
A study reported by the National Institutes of Health (NIH) on April 8, 2013, found a significantly increased risk of acute pancreatitis in type-2 diabetics treated with a DPP-4 inhibitor or glucagonlike peptide 1 (GLP-1). Study subjects who had used this incretin therapy developed cell proliferation resulting in pancreases 40% larger than normal size.
Following adverse event reports between April and June 2017, the FDA disclosed the potential for serious risk of rhabdomyolysis resulting from Januvia and similar drugs.
Januvia lawsuits filed by Philadelphia Januvia drug injury lawyers may allege that Januvia manufacturer Merck & Co.:
- produced and marketed a defective drug with unreasonably dangerous side effects
- released Januvia to the marketplace without adequate pre-market testing
- failed to inform physicians and consumers of the dangerous health risks, including pancreatic cancer, associated with use of Januvia
- failed to include adequate warnings of the risk of pancreatic cancer and other injuries on Januvia labels and package inserts
- failed to warn and advise physicians to monitor Januvia users for signs of developing pancreatitis or pancreatic cancer
- falsely marketed Januvia as a safe and effective drug
- aggressively marketed Januvia with knowledge of high risk of pancreatic cancer and other dangerous side effects
Contact our Philadelphia Januvia Drug Injury Lawyers
Patients with type-2 diabetes who have developed pancreatic cancer or other injuries after using Januvia may be entitled to compensation from Januvia manufacturer, Merck & Co. Contact our Philadelphia Januvia drug injury lawyers, today, to inquire about the possibility of instituting a Januvia lawsuit.